Order of the Ministry of Health of Ukraine No. 801 as of July 17th, 2017 approved the Regulation on the Application of the National List of Essential Medicines when organizing the process of providing the population with medicines in healthcare institutions and facilities that are fully or partially financed from the state and local budgets (hereinafter - the Regulation).
The need to approve the Regulation was determined by the Resolution of the Cabinet of Ministers No. 180 "On Amending and Invalidating Certain Resolutions of the Cabinet of Ministers of Ukraine" as of March 16th, 2017.
The Regulation determines the specifics of the use of medicines included in the National List of Essential Medicines, which are marked with the "√", "*" and "**". For example, "√Do not prescribe to children under 3 months", "*For medical use in case of eclampsia and severe pre-eclampsia. Not applicable for other types of seizures".
The document also provides an explanation of the dosage forms of medicines included in the National List.
It should be noted that healthcare institutions and facilities that are fully or partially funded from the state and local budgets should follow this document when forming the nomenclature for the procurement of medicines from the National List. That is, Resolution of the Cabinet of Ministers "Some Issues of State Regulation of Prices for Medicines and Medical Products" No. 333 as of March 25th, 2009 is applied together with the Regulations.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
